INVEST

Changing the Standard
of Palliative Care

Creating Best-In-Class Treatment Options

As a leader in Cancer Comfort Care, RAMTherapeutics is proud to offer hope and relief to those facing the toughest challenges of cancer treatment. Learn more about our innovative approach and discover how Triamdocaine™ is changing the standard of palliative care for patients around the world.

About RAMTherapeutics

RAM Pharmaceuticals is redefining supportive oncology with Triamdocaine™, a first-in-class investigational therapy developed under an active FDA IND.

Our Cancer Comfort Care Initiative focuses on improving quality of life for patients undergoing radiation and chemotherapy, where oral discomfort remains one of the most debilitating side effects of treatment. Triamdocaine™ leverages a patented dry-powder delivery process designed for precise, localized application within the oral cavity. It’s being evaluated to determine its ability to support oral comfort and maintain treatment adherence — two critical factors that can influence patient outcomes during cancer therapy.

With a U.S. patent extending through 2039 and clinical studies underway, RAM Pharmaceuticals is building a foundation for future oncology-supportive care solutions that align with FDA standards and address a multi-billion-dollar unmet need.

RAMtherapeutics to pioneer a first-of-its-kind solution.

Expanding Horizons

RAM Therapeutics is exploring additional therapeutic areas, including Early Onset Shingles and Genital Herpes. These potential indications are currently under investigation, and no regulatory approval or guarantee of successful development is implied. By expanding our focus, we aim to deliver impactful solutions for even more patient communities, enhancing comfort and care. We are truly passionate about making a positive difference in the lives of patients and their families. Join us on this journey as we continue to innovate and pave the way for therapeutic advancements that transform healthcare for everyone!

Innovating Supportive Cancer Care

RAMtherapeutics, a division of RAM Pharmaceuticals, is advancing next-generation solutions to support patients undergoing cancer treatment. Our lead investigational therapy, Triamdocaine™, is being developed under an active FDA IND with clinical studies scheduled to begin in Q1 2026.

Each year, approximately 650,000 cancer patients receive chemotherapy and 575,000 undergo radiation therapy in outpatient oncology clinics across the United States. Among patients with head and neck cancer, an estimated 60 % – 80 % experience severe oral complications such as oral mucositis during treatment. These side effects can cause intense discomfort, disrupt nutrition, and may even interrupt or delay therapy — significantly impacting quality of life and overall treatment continuity.

At RAMtherapeutics, our goal is to improve the supportive-care experience for these patients through novel delivery technologies that target the source of oral discomfort, helping maintain comfort and function during cancer therapy.

Key Elements of Triamdocaine™ Development

  1. Patient Comfort and Quality of Life Triamdocaine™ is being evaluated for its potential to support oral comfort and reduce localized irritation in patients undergoing radiation or chemotherapy. Our patented dry-powder delivery process enables precise, localized application designed to enhance tolerability and ease of use under professional supervision.
  2. Infection and Barrier Support The localized irritation associated with cancer therapy can create an entry point for bacteria and pathogens. RAMtherapeutics is developing solutions that may help maintain the integrity of the oral environment — a critical factor in reducing complications during treatment.
  3. Nutrition and Treatment Continuity By focusing on comfort and oral function, Triamdocaine™ aims to support the patient’s ability to eat and maintain hydration, both vital for sustaining therapy adherence and overall wellness.
  4. Economic and Systemic Impact The management of oral discomfort related to cancer therapy costs the U.S. healthcare system hundreds of millions annually due to hospitalizations, nutritional support, and infection management. Supportive-care innovations that reduce this burden represent significant value for patients, providers, and payors alike.
 

Investment Outlook

  • Clinical development: Phase 2 study planned for initiation in Q1 2026
  • Regulatory status: Active FDA IND under RAMtherapeutics
  • Intellectual property: Patented delivery technology protected through 2039
  • Market opportunity: The global market for supportive-care therapies addressing oral complications of cancer treatment is projected to exceed USD 2.8 billion by 2033, growing at 7–8 % CAGR
  • Strategic positioning: First-in-class dry-powder delivery platform for localized comfort management in oncology

Forward Vision

RAMtherapeutics is building a pipeline at the intersection of oncology and comfort care — developing therapies that address critical gaps in patient support and advance the future of compassionate cancer care.
Triamdocaine™ is an investigational product. Its safety and effectiveness for the prevention or treatment of oral mucositis, or for any other indication, have not been established or approved by the U.S. Food and Drug Administration (FDA). This content is intended for informational purposes only and is directed toward healthcare professionals and potential investors. It does not constitute promotion or marketing of an approved pharmaceutical product.
Scroll to Top